The incremental value of the pancreas allograft to the survival of Simultaneous Pancreas-Kidney transplant recipients

Paolo R. Salvalaggio, MD, PhD 1,2; Nino Dzebisashvili 1, MS; Brett Pinsky, MS 1; Mark A. Schnitzler, PhD 1; Thomas E. Burroughs, PhD 1; Ralph Graff, MD 1,2; David A. Axelrod, MD 1,3; Daniel C. Brennan, MD 1 and Krista L. Lentine, MD, MS 1,4.

1Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO; 2Department of Surgery, University of Washington, Seattle, WA; 3Department of Surgery, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, 4Division of Nephrology, Saint Louis University School of Medicine, St. Louis, MO.

Institution at which work was performed: Saint Louis University Center for Outcomes Research, St. Louis, MO.

Corresponding author and contact for information:
Paolo R. Salvalaggio, MD, PhD
E-mail: psalvala@u.washington.edu

Submitted 18 September 2008 and accepted 6 January 2009.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association, publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes Care in print and online at http://care.diabetesjournals.org.
Objective: To quantify the incremental survival benefit of the pancreas allograft in Simultaneous Pancreas-Kidney (SPK) transplant recipients.

Research design and methods: Data from the national transplant database from 2000 to 2007 was analyzed. SPK recipients who had functioning allografts to one-year post-transplant (n=3,304) were compared to those who had failure of the renal (n=233) or pancreatic graft (n=112). The main outcome was 10-year projected life-years (LYs) of patient survival beyond the first transplant anniversary.

Results: Recipients with function of both organs accrued 9.4 LYs following transplantation. Projected survival in patients with kidney failure was reduced to 2.5 LYs. Pancreas failure reduced predicted survival to 8 LYs. Renal allograft failure impacts life expectancy significantly (aHR=12.13). However, pancreas allograft failure was also associated with reduced survival (aHR=2.62).

Conclusions: While the majority of the survival benefit of SPK transplant is due to the renal transplant, pancreas allograft function does contribute to patient survival.

Abbreviations:
(a)HR- (adjusted) Hazard Ratio
DM-Diabetes Mellitus
LY-life-years
OPTN-Organ Procurement and Transplant Network
SPK- Simultaneous Pancreas-Kidney transplantation
The American Diabetes Association considers Simultaneous Pancreas-Kidney (SPK) transplantation the treatment of choice for patients with type I diabetes (DM) and chronic renal failure (1). Previous studies have questioned the incremental benefit of the pancreas allograft compared with kidney transplant alone for the uremic diabetic patient (2-9). This study aims to quantify the incremental value of the pancreas allograft function to the survival of SPK transplant recipients.

RESEARCH DESIGN AND METHODS

A retrospective cohort study from all SPK transplant recipients between January 1, 2000 and December 31, 2007 was performed utilizing data from the Organ Procurement Transplant Network (OPTN) research files. Included were adults (age >18 years), first-SPK transplant recipients with chronic renal failure due to type I DM. The primary outcome was projected incremental life years (LYs) attributed to each allograft’s function based on data from recipients of SPK transplantation with dual function (n=3,304), isolated kidney graft failure (n=233) or pancreas graft failure (n=112) (10).

Peri-operative mortality risk raises the hazard of death early after transplant, complicating the projection of long-term survival with a single mathematical function. We utilized a two-part strategy to quantify the implications of organ-specific allograft failure on patient survival. First, we estimated the independent associations of kidney and pancreas failure with relative mortality risk (adjusted hazards ratio, aHR) by multivariable Cox regression, using five years of observed registry data. We then computed long-term survival expectations by parametric regression assuming a Weibull survival function. The survival expectation of patients who sustained function of both organs was estimated as the reference by censoring of time-to-death at the first occurrence of kidney or pancreas failure, and the area under a 10-year survival projection beyond the first transplant anniversary was the computed as the LY expectation over 10 years. The daily mortality hazard in the reference group was computed as the difference in projected survival between day x and day (x+1). Survival expectations with organ-specific graft failure were quantified by multiplying reference-group daily hazards by the relative hazard ratio associated computed for graft failure in the Cox regressions, and sequentially subtracting estimated survival decrements at each day over 10-years.

RESULTS

Survival was projected for 3,649 SPK recipients who survived with functioning allografts to the first anniversary following SPK over a possible 10 year time horizon. The long-term mortality impact of transplant failure is substantially greater following kidney failure (aHR of 12.13 for death >30 days after organ failure) than after pancreas failure (aHR of 2.62 for death > 30 days after organ failure).

In our projection, loss of both kidney and pancreas allograft function had a substantial impact on the estimated survival for SPK patients over the 10 years post-transplant (Figure 1). Overall, recipients of SPK transplants who had kidney allograft failure lost 6.9 LYs of the 9.4 LYs expected for patients with preserved function of both organs. Pancreas allograft failure was associated with a reduction of 1.4 LYs of the 9.4 LYs expected after SPK transplantation with long-term sustained function of both grafts. Thus, kidney failure reduced expected survival by 85% while pancreas lost reduced projected survival by 15% among SPK recipients.
Value of pancreas allograft in kidney-pancreas transplantation

DISCUSSION

Understanding of the independent value of the pancreas allograft is vital to the assessment of the benefits of SPK transplantation and assessment of allocation policy. We chose to begin the analysis after 1-year to avoid the initial post-operative period when most of surgical and medical complications often occur but most of benefits have not yet accrued (8,11). The timing of graft failure events might impact the calculation LY gain from a transplant, but in our pilot studies it did not modify the main results herein presented.

We demonstrated that while the likelihood of death after allograft failure is substantially greater following kidney failure, pancreas loss does have a detrimental impact on patient survival. This analysis is limited by our inability to determine if the reduction in survival was the result of a complication from the graft loss itself or from the loss of function over time. The natural experiment observed using this method eliminated the major weaknesses of previous studies: selection bias of comparison of SPK and isolated renal transplant recipients who may differ in terms of both patient and donor characteristics (2-9). One could argue that the independent value of each allograft might be difficult to isolate due to the interactive processes between both organs (e.g. a reduction in rejection due to the presence of an additional organ). However, we did not find any data documenting this effect.

We estimated the kidney and pancreas allograft function to contribute approximately 85% and 15%, respectively, to the expected patient LY survival benefit of SPK transplantation. There is a clearly an identifiable, independent LY benefit from the pancreas allograft. Based on our data, launching of new allocation policies that will augment the volume of SPK transplantation should be supported.

In addition to the known limitations of retrospective registry studies, our findings have other limitations. The OPTN Registry does not carry indices of glycemic control. This prevents analysis of the relationship between strict normoglycemia and pancreas allograft LY gain. We have not included the impact on quality of life produced by differential allograft survival in specific clinic scenarios, such as patients with brittle diabetes (12). Finally, there are inherent methodological limitations of any attempt to predict future outcomes based on available data and assumptions. However, similar projections have performed well when compared with actual outcomes suggesting that this method is robust.

In summary, the majority of LY gain following SPK is related to preserved renal allograft function. The pancreas allograft appears to have an important, but smaller, independent role in adding LY for type I diabetics with chronic renal failure.

ACKNOWLEDGMENTS

The data reported here have been supplied by United Network for Organ Sharing as the contractor for the Organ Procurement Transplant Network. An abstract describing portion of this work was accepted for presentation at the 2008 American Transplant Congress in Toronto, Canada. The authors thank Connie Davis, MD and Ian de Boer, MD for revising the manuscript.

Disclosure: The authors have no relevant conflict of interest to disclose.

Funding Sources: Dr. Salvalaggio is supported by a grant from the American Society of Transplantation. Dr. Lentine is supported by a grant from the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK), K08-0730306.

Role of sponsor: The interpretation and reporting of these data are the sole responsibility of the authors and should in no way be seen as representing official policy of
or interpretation by the Organ Procurement Transplant Network, the American Society of Transplantation or the United States government.

**Author contributions:** Study concept and design- Salvalaggio; Acquisition of data- Salvalaggio, Schnitzler, Lentine; Analysis and interpretation of data- Salvalaggio, Schnitzler, Lentine; Critical revision of the manuscript with important intellectual content- Salvalaggio, Schnitzler, Lentine, Burroughs, Graff, Brennan, Axelrod; **Statistical expertise:** Dsebisashvili, Pinsky, Schnitzler, Lentine; **Obtained funding:** Salvalaggio, Schnitzler, Lentine; **Study supervision:** Salvalaggio, Schnitzler, Lentine.
REFERENCES

**Figure 1. Survival-plot among patients with long-term sustained function of both allografts, compared to expected survival with organ-specific graft failure.**

Legend:
- **SPK recipient, no graft failure (n=3,304)**
- **SPK recipient, Pancreas allograft failure, sustained Kidney allograft function (n=233)**
- **SPK recipient, Kidney allograft failure, sustained Pancreas allograft function (n=112)**

Footprint:
Δ = delta, the difference in patient survival (in life-years) caused by loss of the graft
LY = life-years

*Depicted scenarios assumed allograft failures occurred at day 365 after SPK transplant (time zero on the survival plot).